Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 13, showing 5 Applications out of 61 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s) Application Status

1.

ECCT/20/06/04   ANTICOV (01 COV)
    An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Mbagathi Infectious Disease Hospital (Nairobi City county)
2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county)
 
Trial Status Not yet recruiting
Protocol Date 16-06-2020
View

2.

ECCT/20/06/02   EMPACTA Covid19 Study
    A RANDOMIZED, DOUBLE-BLIND, Placebo-Controlled, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID‑19 PNEUMONIA   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
AgaKhan University Hospital Nairobi
 
Trial Status Recruiting
Protocol Date 02-06-2020
View

3.

ECCT/20/05/02   COPCOV
    Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)   
Principal Investigator(s)
1. Anthony Oliwa Etyang
Site(s) in Kenya
1. KEMRI - Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county)
2. KEMRI-Centre for Global Health Research (CGHR) (Kisumu county)
 
Trial Status Not yet recruiting
Protocol Date 09-04-2020
View

4.

ECCT/20/04/03   518 & 525-SHAN6™
    Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants.    Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age   
Principal Investigator(s)
1. Bernhards Ogutu
2. Godfrey Allan Otieno
3. Videlis Nduba
4. Lucy Chepkurui Koech
5. samuel Gurrion Ouma
6. Janet Oyieko
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
3. KEMRI Kondele Children’s Hospital (Kisumu county)
4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county)
5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county)
6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county)
7. CRDR_Siaya Annex(Back-up site) (Siaya county)
 
Trial Status Not yet recruiting
Protocol Date 08-01-2020
View

5.

ECCT/19/12/02   VPM1002 Phase III PoI
    A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants.     
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI-CRDR Nairobi (Nairobi City county)
2. KEMRI-CRDR Siaya (Siaya county)
 
Trial Status Not yet recruiting
Protocol Date 01-07-2019
View